CompletedNCT00152035
This study exists to understand whether this type of care is both safe enough and useful enough to take further. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.
ADHDOtherFrom 18 Years to 55 Years
- Countries
- Global
- Sponsor
- Shire
- Condition
- ADHD
CompletedNCT05016102
This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
ADHDOtherFrom 8 Years to 12 Years
- Countries
- Global
- Sponsor
- National Taiwan Normal University
- Condition
- ADHD
CompletedNCT00339027
This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.
ADHDOtherFrom 3 Years to 5 Years
- Countries
- United States
- Sponsor
- University of Miami
- Condition
- ADHD
CompletedNCT02777931
This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.
ADHDOtherFrom 12 Years to 17 Years
- Countries
- United States
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Condition
- ADHD
CompletedNCT01232361
This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.
ADHDOtherFrom 6 Years to 25 Years
- Countries
- United States
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Condition
- ADHD
CompletedNCT00429273
This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
ADHDOtherFrom 7 Years to 14 Years
- Countries
- United States
- Sponsor
- University of California, Los Angeles
- Condition
- ADHD
CompletedNCT03609619
This study exists to explore whether the medication AEVI-001 could improve care and understanding. Researchers are trying to understand what the medication AEVI-001 could change in day-to-day care and decision-making.
ADHDOtherFrom 6 Years to 17 Years
- Countries
- United States
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Condition
- ADHD
CompletedNCT04270812
This study exists to see whether this type of care is workable and worth testing more broadly. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
ADHDOtherFrom 13 Years to 17 Years
- Countries
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Condition
- ADHD
CompletedNCT03618030
This study exists to compare options and see whether the medication PRC-063 offers something meaningfully different. Researchers are trying to understand how people respond to the medication PRC-063 in practice and what may need to be adjusted.
ADHDOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- Purdue Pharma, Canada
- Condition
- ADHD
CompletedNCT02493777
This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.
ADHDOtherFrom 6 Years to 12 Years
- Countries
- United States
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Condition
- ADHD
CompletedNCT02520388
This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.
ADHDOtherFrom 6 Years to 12 Years
- Countries
- United States
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Condition
- ADHD
CompletedNCT02884544
This study exists to understand whether the medication Delayed is both safe enough and useful enough to take further. Researchers are trying to understand whether the medication Delayed can give earlier or clearer feedback during care.
ADHDOtherFrom 6 Years to 12 Years
- Countries
- United States
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Condition
- ADHD
CompletedNCT03460652
This study exists to better understand the safety of a digital app or remote support tool and how manageable it feels in practice. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
ADHDOtherFrom 6 Years to 12 Years
- Countries
- United States
- Sponsor
- Zevra Therapeutics
- Condition
- ADHD
CompletedNCT04402528
This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
ADHDOtherFrom 3 Years to 5 Years
- Countries
- United States
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Condition
- ADHD
CompletedNCT02897362
This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
ADHDOtherFrom 13 Years to 17 Years
- Countries
- United States
- Sponsor
- Duke University
- Condition
- ADHD
CompletedNCT00152022
This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand whether a medication treatment can improve sleep, daily rhythms, and longer-term stability.
ADHDOtherFrom 18 Years to 55 Years
- Countries
- Global
- Sponsor
- Shire
- Condition
- ADHD
CompletedNCT03247543
This study exists to understand whether the medication SPN-812 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication SPN-812 in practice and what may need to be adjusted.
ADHDOtherFrom 6 Years to 11 Years
- Countries
- United States
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Condition
- ADHD
CompletedNCT03265119
This study exists to explore whether the medication AEVI-001 could improve care and understanding. Researchers are trying to understand what the medication AEVI-001 could change in day-to-day care and decision-making.
ADHDOtherFrom 6 Years to 17 Years
- Countries
- United States
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Condition
- ADHD
CompletedNCT02811211
This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.
ADHDOtherFrom 6 Years to 17 Years
- Countries
- United States
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Condition
- ADHD
CompletedNCT03233867
This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
ADHDOtherFrom 6 Years to 17 Years
- Countries
- United States
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Condition
- ADHD
CompletedNCT03006367
This study exists to better understand the safety of the medication NFC-1 and how manageable it feels in practice. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.
ADHDOtherFrom 6 Years to 17 Years
- Countries
- United States
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Condition
- ADHD
WithdrawnNCT00458445
This study exists to explore whether the medication SPD465 could improve care and understanding. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.
ADHDOtherFrom 19 Years to 25 Years
- Countries
- United States
- Sponsor
- Shire
- Condition
- ADHD
CompletedNCT04167189
This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.
ADHDOtherFrom 7 Years to 49 Years
- Countries
- United States
- Sponsor
- PhenoSolve, LLC
- Condition
- ADHD
CompletedNCT03247530
This study exists to understand whether the medication SPN-812 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication SPN-812 in practice and what may need to be adjusted.
ADHDOtherFrom 6 Years to 11 Years
- Countries
- United States
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Condition
- ADHD
CompletedNCT01244490
This study exists to compare options and see whether this type of care offers something meaningfully different. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.
ADHDOtherFrom 6 Years to 17 Years
- Countries
- Austria, Canada, France, Germany, Ireland, Italy, Poland, Romania, Spain, Sweden, Ukraine, United Kingdom, United States
- Sponsor
- Shire
- Condition
- ADHD